Sigilon Therapeutics Stock Price, News & Analysis
Company Description
Sigilon Therapeutics (NASDAQ: SGTX) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $56.2M.
SGTX stock has declined 100.0% over the past year.
This page provides a comprehensive overview of SGTX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Sigilon Therapeutics (SGTX) stock. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $56.2M, SGTX is classified as a micro-cap stock with approximately 2.5M shares outstanding.
Latest News
Sigilon Therapeutics has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition, stock split, earnings, conferences, management. View all SGTX news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
SGTX Company Profile & Sector Positioning
Sigilon Therapeutics (SGTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing SGTX often look at related companies in the same sector, including Camp4 Therapeutics Corp. (CAMP), Cue Biopharma Inc (CUE), Pds Biotechnology Corporation (PDSB), JUPITER NEUROSCIENCES, INC. (JUNS), and Bioxcel Therapeutics Inc (BTAI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SGTX's relative position within its industry.